Pulmonary vascular disease and cardiopulmonary function
Research activity includes pulmonary arterial hypertension, with attention to right ventricular diastolic function and treatment effects on cardiac performance.
- Right ventricular function
- Pulmonary arterial hypertension
- Cardiopulmonary remodeling
The sponsor also supports work on therapies aimed at improving functional outcomes in advanced pulmonary vascular disease.
Interstitial lung disease and fibrotic lung disorders
Clinical research covers idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, including disease states marked by eosinophilia and declining lung capacity.
- Idiopathic pulmonary fibrosis
- Progressive pulmonary fibrosis
- Forced vital capacity
Investigations in this area focus on respiratory impairment, inflammatory activity, and preservation of pulmonary function.
Rare endocrine and neuroendocrine conditions
Supported trials address congenital adrenal hyperplasia and small intestinal neuroendocrine neoplasms, reflecting interest in inherited endocrine disease and regionally restricted neuroendocrine malignancy.
- Congenital adrenal hyperplasia
- Small intestinal neuroendocrine neoplasms
- Relapse-free survival
This research includes reproductive and oncologic outcomes relevant to rare disease management.
Chronic airway infection and bronchiectasis
Work in bronchiectasis includes management of Pseudomonas aeruginosa airway colonisation and restoration of respiratory microbiological control.
- Bronchiectasis
- Pseudomonas aeruginosa
- Airway culture negativity
The sponsor’s clinical portfolio also reflects interest in infection-associated airway disease and chronic suppurative lung conditions.
Allergic and inflammatory skin disease
Research extends to chronic spontaneous urticaria, with emphasis on symptom burden and control of persistent mast cell-driven skin inflammation.
- Chronic spontaneous urticaria
- Urticaria Activity Score
- Inflammatory allergic disease
This area adds an immunology-focused component to the sponsor’s broader respiratory and rare disease portfolio.
